Milestone Scientific, Inc. reports Q2 2026 revenue of $2.8 million, up 22% YoY, driven by medical segment growth; guidance reaffirmed despite caution for Q3.

Milestone Scientific, Inc. reported Q2 2026 revenue of $2.8 million, a 22% increase compared to $2.3 million in Q2 2025, exceeding analyst expectations. The growth was fueled primarily by significant gains in the medical segment, driven by the company's innovative CompuFlow technology.

Key Takeaways

• Total revenue increased to $2.8 million, up 22% YoY, supported by strong medical and dental sales.
• Medical segment revenue surged 231% YoY, driven by the expanding adoption of CompuFlow technology.
• Gross margin tightened to 67.2% from 69.6% YoY, attributed to rising product costs.
• Operating expenses decreased by 4.2% to approximately $3 million, reflecting disciplined cost management.
• Reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million, anticipating continued growth in the medical business.

Strong Growth in Medical Segment

The standout story for Milestone Scientific this quarter is the remarkable 231% year-over-year growth in its medical segment, which contributed significantly to the overall revenue increase. The company’s CompuFlow technology is gaining traction, with growing physician acceptance and an expanding footprint in reimbursement from Medicare and commercial payers. CEO Eric Hines emphasized the successful launch of the CompuFlow Advisor program, which has enhanced procedural adoption in various jurisdictions.

CompuFlow's efficacy has been validated through a peer-reviewed study published in Operative Neurosurgery, showing a 91% reduction in complication odds during procedures. This validation not only reinforces the product's value but also supports increased utilization across critical medical procedures, including epidural steroid injections and spinal cord stimulator implantations.

Margin Pressures Amid Cost Increases

While the company celebrated revenue growth, it faced challenges in gross margin, which fell to 67.2% from 69.6% in the prior year. This decrease is primarily due to rising product costs, including tariffs and increased expenses associated with certain imported components. Although operating expenses decreased by 4.2% to $3 million, the company must navigate these cost pressures to maintain profitability as it scales its operations.

Guidance Reaffirmed but Cautious Outlook for Q3

Management reaffirmed its full-year 2026 revenue guidance of $9.8 million to $10.2 million, projecting continued double-digit growth driven by the medical segment. However, CEO Eric Hines cautioned investors about Q3, highlighting the seasonal slowdown typically experienced during summer months and the absence of two substantial international orders that benefited Q2. This tempered outlook indicates a need for careful modeling as the company continues to ramp up direct sales efforts and expand its reimbursement footprint.

Analyst Q&A Insights

During the Q&A session, analysts sought clarity on the company’s reimbursement efforts and international order expectations. Hines confirmed that two Medicare Administrative Contractors (MACs) currently cover the CompuFlow technology in three jurisdictions across 13 states, representing approximately 30-35% of the U.S. population. There are ongoing efforts to secure additional MACs, with expectations to expand further westward.

Bruce Jackson of Stonex inquired about the potential decline in sales for Q3, with Hines projecting revenue to fall between $2.3 million to $2.5 million. This forecast reflects the anticipated seasonal trends and the absence of repeat orders that were recognized in Q2.

Frequently Asked Questions

Did Milestone Scientific, Inc. Common Stock beat earnings estimates in Q2 2026?

Yes, Milestone reported Q2 2026 revenue of $2.8 million, exceeding analyst expectations of approximately $2.3 million.

What is the expected revenue for Milestone Scientific in Q3 2026?

Management projected Q3 revenue in the range of $2.3 million to $2.5 million, indicating a seasonal decline compared to Q2.

How has the CompuFlow technology performed in the market?

CompuFlow revenue grew by 231% YoY, indicating strong market acceptance and adoption, supported by favorable reimbursement outcomes from Medicare.

What challenges is Milestone facing regarding gross margin?

The gross margin has declined to 67.2% due to rising product costs and tariffs, which the company must manage as it scales operations.

In summary, while Milestone Scientific's Q2 results showcase solid revenue growth and momentum in the medical segment, the upcoming quarters present challenges, particularly with seasonal sales fluctuations and margin pressures. Investors will be watching closely as the company continues its strategic initiatives in expanding market penetration and operational efficiency.

This analysis is based on public earnings call materials and is not investment advice.